X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (57) 57
humans (55) 55
hematology (48) 48
male (39) 39
middle aged (35) 35
female (32) 32
aged (30) 30
adult (28) 28
oncology (22) 22
leukemia, lymphocytic, chronic, b-cell - drug therapy (21) 21
treatment outcome (20) 20
rituximab (17) 17
abridged index medicus (16) 16
aged, 80 and over (16) 16
antineoplastic agents - therapeutic use (15) 15
chronic lymphocytic leukemia (15) 15
cancer (13) 13
hemic and lymphatic diseases (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
chronic lymphocytic-leukemia (12) 12
hematology, oncology and palliative medicine (11) 11
leukemia (11) 11
article (10) 10
leukemia, lymphocytic, chronic, b-cell - genetics (10) 10
recurrence (10) 10
transplantation (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
chemotherapy (9) 9
disease-free survival (9) 9
expression (9) 9
survival (9) 9
antineoplastic agents - administration & dosage (8) 8
apoptosis (8) 8
care and treatment (8) 8
cyclophosphamide (8) 8
fludarabine (8) 8
hematopoietic stem cell transplantation (8) 8
immune system diseases (8) 8
activation (7) 7
analysis (7) 7
antineoplastic agents - adverse effects (7) 7
drug therapy (7) 7
ibrutinib (7) 7
management (7) 7
open-label (7) 7
patients (7) 7
risk factors (7) 7
cells (6) 6
clinical trials and observations (6) 6
initial therapy (6) 6
leukemia, lymphocytic, chronic, b-cell - metabolism (6) 6
lymphomas (6) 6
mutation (6) 6
pyrazoles - therapeutic use (6) 6
pyrimidines - therapeutic use (6) 6
therapy (6) 6
age factors (5) 5
antibodies, monoclonal - therapeutic use (5) 5
bone-marrow-transplantation (5) 5
chronic lymphocytic leukaemia (5) 5
clinical trials (5) 5
clinical trials as topic (5) 5
cll (5) 5
dosage and administration (5) 5
drug administration schedule (5) 5
idelalisib (5) 5
immunology (5) 5
leukemia, lymphocytic, chronic, b-cell - mortality (5) 5
leukemia, lymphocytic, chronic, b-cell - therapy (5) 5
lymphoid neoplasia (5) 5
medicine & public health (5) 5
non-hodgkin lymphoma (5) 5
outcomes (5) 5
pharmacology (5) 5
prognosis (5) 5
research (5) 5
stem cells (5) 5
survival analysis (5) 5
time factors (5) 5
transplantation, homologous (5) 5
antibodies, monoclonal - administration & dosage (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
btk (4) 4
chemoimmunotherapy (4) 4
chronic lymphatic leukemia (4) 4
cyclophosphamide - administration & dosage (4) 4
diagnosis (4) 4
dose-response relationship, drug (4) 4
drug resistance, neoplasm (4) 4
hematopoietic stem cell transplantation - methods (4) 4
hematopoietic stem cells (4) 4
immunosuppressive agents - therapeutic use (4) 4
inhibitor (4) 4
lenalidomide (4) 4
leukemia, lymphocytic, chronic, b-cell - diagnosis (4) 4
lymphoma (4) 4
maximum tolerated dose (4) 4
multicenter (4) 4
multivariate analysis (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 01/2018, Volume 131, Issue 2, pp. 156 - 157
In this issue of Blood , Bartlett et al share their experience with the use of ibrutinib in patients with relapsed or refractory follicular lymphoma (FL). 1 
HEMATOLOGY | FOLLICULAR LYMPHOMA
Journal Article
Expert review of hematology, 06/2018, Volume 11, Issue 6, p. 495
Acalabrutinib, a selective Bruton tyrosine kinase (BTK) inhibitor, was granted accelerated approval by the FDA on 31 October 2017 for the treatment of patients... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 2810 - 2810
Introduction: Idelalisib (IDELA, Zydelig®) is the first-in-class PI3Kδ inhibitor and is approved in the U.S. as an oral monotherapy for relapsed / refractory... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2016, Volume 374, Issue 4, pp. 323 - 332
Acalabrutinib is an irreversible inhibitor of Bruton's tyrosine kinase with greater specificity for the enzyme than the first-in-class agent, ibrutinib. It had... 
B-CELL RECEPTOR | MEDICINE, GENERAL & INTERNAL | ACTIVATION | IN-VIVO | X-LINKED AGAMMAGLOBULINEMIA | IBRUTINIB | BTK | PCI-32765 | TYROSINE KINASE INHIBITOR | LYMPHOMA | OPEN-LABEL | Recurrence | Benzamides - pharmacokinetics | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Diarrhea - chemically induced | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Antineoplastic Agents - adverse effects | Female | Antineoplastic Agents - pharmacokinetics | Benzamides - adverse effects | Headache - chemically induced | Chromosome Deletion | Protein Kinase Inhibitors - pharmacokinetics | Administration, Oral | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Agammaglobulinaemia Tyrosine Kinase | Pyrazines - pharmacokinetics | Pyrazines - adverse effects | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Treatment outcome | Usage | Care and treatment | Safety and security measures | Lymphocytic leukemia | Analysis | Clinical trials | Pharmacology | Dosage and administration | Pharmacokinetics | Antineoplastic agents | Tyrosine | Headache | Pharmacodynamics | Transformation | Chronic lymphatic leukemia | Inhibitor drugs | Leukemia | Diarrhea | Chromosome deletion | Lymphatic leukemia | Kinases | Lymphoma | Bruton's tyrosine kinase | Patients | Clonal deletion | Lymphomas | Safety | Drug therapy | Lymphocytosis | Protein-tyrosine kinase | Chromosome 17 | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 26, pp. 2530 - 2541
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 12/2014, Volume 20, Issue 23, pp. 5869 - 5874
Over the past two decades, slow but deliberate progress has been made in understanding the genetics of chronic lymphocytic leukemia (CLL) and how the... 
TRIAL | ONCOLOGY | CYCLOPHOSPHAMIDE | RITUXIMAB | INITIAL THERAPY | IBRUTINIB | REGIMEN | INHIBITOR | FLUDARABINE | CANCER | T-LYMPHOCYTES | Antineoplastic Agents - therapeutic use | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Protein Kinase Inhibitors - therapeutic use | Humans | Leukemia, Lymphocytic, Chronic, B-Cell - etiology
Journal Article
Expert opinion on pharmacotherapy, 09/2018, p. 1
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A11803 - A11803
IntroductionHeart failure (HF) outcomes continue to improve. However, increasing emphasis has recently been placed on the potential impacts of cancer on HF and... 
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A11805 - A11805
IntroductionCancer is a pro-thrombotic state, associated with a substantial increase in the risk of venous thromboembolism (VTE). Yet, little is known about... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 5878 - 5878
Introduction: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western world. Treatment selection in CLL is dependent upon a number... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 3045 - 3045
Background B-cell receptor signaling inhibition (BCRi) is an effective treatment (trtmt) for patients (pts) with chronic lymphocytic leukemia (CLL), but... 
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 4724 - 4724
Introduction Targeted therapies are dramatically changing the treatment landscape for chronic lymphocytic leukemia (CLL). Given the rapid pace of new approvals... 
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2018, Volume 71, Issue 11, p. A279
Journal Article
Cancer Research, ISSN 0008-5472, 07/2016, Volume 76, Issue 14 Supplement, pp. 4697 - 4697
Chronic lymphocytic leukemia (CLL) is a malignancy characterized by the progressive accumulation of CD19 B-cells capable of overcoming their regulated life... 
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A11112 - A11112
BackgroundThe use of contemporary advanced cardiovascular interventions (ACI) has dramatically increased. Concurrently, survivorship from cancer continues to... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 3148 - 3148
Abstract BACKGROUND: Ibrutinib is an irreversible inhibitor of BTK in the B-cell receptor signaling cascade and is widely used to treat chronic lymphocytic... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4185 - 4185
Abstract Introduction: Combined obinutuzumab (O) and lenalidomide (L) has demonstrated safety and preliminary efficacy in follicular lymphoma1. Venetoclax (V),... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.